Biomerica commences $2.23M private placement of 1.394M shares at $1.60
- Biomerica commences private placement of 1,393,705 shares at $1.60 each
- Transaction yields approximately $2.23 million in gross proceeds
- No warrants or discounted securities included in the deal structure
- Key stakeholders including board members and executives participated
- Funds to support balance sheet and strategic evaluation process
*this image is generated using AI for illustrative purposes only.
Biomerica, Inc. (NASDAQ: BMRA) has commenced a private placement of 1,393,705 unregistered shares of common stock priced at $1.60 per share. The company entered into definitive agreements with institutional and individual investors for the transaction.
The financing is expected to provide approximately $2.23 million in gross proceeds to Biomerica. The shares were priced at $1.60 at the time the definitive agreements were executed. The transaction structure includes no warrants or discounted securities.
Participation and Structure
Key stakeholders participated in the financing, including B. Riley Principal Capital, certain executives and employees of B. Riley Securities, Inc., Biomerica’s Chief Executive Officer, and all members of the Board of Directors. This participation reflects alignment between outside investors and company leadership.
| Metric | Value |
|---|---|
| Gross Proceeds | $2.23 million |
| Price Per Share | $1.60 |
| Shares Issued | 1,393,705 |
| Pro Forma Shares Outstanding | 4,588,968 |
| Dilution (Pro Forma) | 30.4% |
Following closing, the new shares will represent approximately 30.4% of the pro forma shares outstanding. The total pro forma share count is expected to be 4,588,968.
Strategic Outlook
B. Riley Securities will assist Biomerica in reviewing, evaluating, and negotiating potential acquisitions, mergers, joint ventures, partnerships, spin-offs, and other strategic combinations. The goal is to maximize long-term shareholder value through these potential transactions.
Proceeds are intended to strengthen the balance sheet and fund operations while the Board evaluates potential partnerships and business combinations. Biomerica develops and manufactures diagnostic test systems, primarily focusing on gastrointestinal and inflammatory diseases. The company markets advanced diagnostic and therapeutic products used at the point-of-care and in hospital laboratories.
How will the 30.4% pro forma dilution impact Biomerica's earnings per share and stock valuation in the near term?
What specific criteria is B. Riley Securities using to identify potential acquisition targets in the gastrointestinal diagnostics sector?
Will the $2.23 million in gross proceeds be sufficient to fund operations until a strategic partnership or merger is finalized?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
